Open AccessComplete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report
Author(s) -
Changhong Yu,
Gang Wu,
Simeng Zhang,
Yunpeng Liu,
Junle Qu,
Xiujuan Qu
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s320477
Subject(s) - medicine , bevacizumab , capecitabine , irinotecan , colorectal cancer , response evaluation criteria in solid tumors , oxaliplatin , regorafenib , oncology , regimen , chemotherapy , telangiectasia , cancer , gastroenterology , surgery , progressive disease
Doublet or triplet chemotherapy plus or minus targeted drugs can achieve a high objective response rate (ORR) and are currently considered to be the backbone of conventional therapy for liver metastatic colorectal cancer (mCRC). However, current biomarkers (such as UGT1A1 and DPYD) are limited to the prediction of toxicity and there are no effective biomarkers to predict chemotherapy response. Therefore, personalized cancer chemotherapy underpinned by genomic alterations in mCRC has received increasing attention.